Welcome : Guest

ProMIS™ Neurosciences, Inc. (Canada) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about ProMIS™ Neurosciences, Inc., which is principally a Development-Stage Biotechnology Company. Illustrated with 9 tables, the report showcases the company's key markets and market position as against its competitors operating in the industry.

Code: PCP-74398
Price: $450
Company Type: Public
Pages: 10
Date: February 2017
Market Data Tables: 9

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Neuroendocrine Tumors (NETs)......2
Table 1: Neuroendocrine Tumors (NETs) by Area in the US (2015) - Percentage Share Breakdown by Value for Gls & Unknown, Lung & Thymus, and Pancreas......2
Table 2: No. of Neuroendocrine Tumours Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......3
Neuromodulation......4
Table 3: Neuromodulation Market by Category in the US (2015) - Percentage Share Breakdown by Value for Deep Brain, Sacral Nerve, Spinal Cord, and Vagus Nerve......4
Table 4: Neuromodulation Market by Category Worldwide (2016) - Percentage Share Breakdown by Value for Deep Brain Stimulation, Sacral Nerve Stimulation, Spinal Cord Stimulation (Pain), Vagus Nerve Stimulation, and Others......5
Table 5: Neuromodulation Market by Company Worldwide (2014) - Percentage Breakdown by Value Sales for Boston Scientific Corporation, Cyberonics, Inc., Medtronic, Inc., and St. Jude Medical, Inc.......6
Alzheimer Diseases......7
Table 6: Market Shares of Leading Alzheimer Disease Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Forest Laboratories, Inc., Johnson & Johnson, Novartis International AG, Pfizer, Inc., and Others......7
Table 7: Market Shares of Leading Therapeutic Providers (Alzheimer's Disease, Bone Diseases, Cardiology, CNS, Dermatology, Diabetes/Metabolic, Epilepsy, G.I./Ulcer, HBV/HCV, Infectious Disease, Multiple Sclerosis, Obesity, Onc./Hematology, Ophthalmology, Orphan Disease, Pain Management, Respiratory, Rheumatology, Sleep Disorders, Urinary Incont., and Women's Health) by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Biogen Idec, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Endo International Plc, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., and Others......8
Neuroendocrine Tumors......9
Table 8: Market Shares of Leading Medication for the Treatment of Acromegaly & Neuroendocrine Tumors Worldwide (2015) - Percentage Share Breakdown by Value for Lanreotide, Octreotide Immediate-release (IR), and Octreotide Long-acting Release (LAR)......9
Neuromodulation Devices......10
Table 9: Market Shares of Leading Neuromodulation Device Manufacturers Worldwide (2014) - Percentage Breakdown by Value for Boston Scientific Corporation, Cyberonics, Inc., Medtronic, Inc. and St. Jude Medical, Inc.......10